/

Sociétés

Fo

Non vérifié

Forlong Biotechnology

Ce que nous écrivons

BiotechnologieIndustrie pharmaceutiqueMédecine - DiversOncologieSanté

8 communiqués de presse

Voir tous les communiqués de presse

21/04/2026

Expos

Analyse de marché

Science

Biotechnologie

Industrie pharmaceutique

Oncologie

Santé Publique

Santé

Médecine - Divers

Forlong Biotechnology to Present Clinical Data from the First-in-human Study for FL115 (IL-15 Superagonist) in US Patients with Advanced Solid Tumors at 2026 ASCO Annual Meeting

Source

Forlong Biotechnology

Émetteur

1.00

0

15/04/2026

Industrie

Oncologie

Santé

Médecine - Divers

Science

Industrie pharmaceutique

Biotechnologie

Forlong Biotechnology Announced CMC Readiness to Initiate GMP Batch Production to Support Upcoming Pivotal Clinical Trial for FL115 (IL-15 Superagonist) in Nonmuscle Invasive Bladder Cancer (NMIBC)

Source

Forlong Biotechnology

Émetteur

1.00

0

17/03/2026

Événements

Industrie

Biotechnologie

Santé

Industrie pharmaceutique

Médecine - Divers

Oncologie

Forlong Biotechology to Present Preclinical Data from FL115, a novel interleukin-15 (IL-15) superagonist, and FL116, a PD-1/interleukin-18 (IL-18) bispecific antibody, at the 2026 AACR Annual Meeting

Source

Forlong Biotechnology

Émetteur

1.00

0

07/01/2026

Événements

Industrie

Oncologie

Santé

Médecine - Divers

Science

Industrie pharmaceutique

Biotechnologie

Forlong Biotechology Announced Activation of Phase Ib/II Study of FL115 (IL-15 Superagonist) in combination with anti-PD-1 Antibody for Patients with Advanced Solid Tumor and Acceptance of IND for FL115 Subcutaneous Injection by NMPA

Source

Forlong Biotechnology

Émetteur

1.00

0

30/10/2025

Oncologie

Santé

Médecine - Divers

Science

Industrie pharmaceutique

Biotechnologie

Événements

Industrie

Forlong Biotechology to Present Clinical Data from FL115, a novel interleukin-15 (IL-15) superagonist, in Late-breaking Session at 40th SITC Annual Meeting

Source

Forlong Biotechnology

Émetteur

1.00

0

30/10/2025

Événements

Industrie

Oncologie

Santé

Médecine - Divers

Science

Industrie pharmaceutique

Biotechnologie

Forlong Dosed First Patient in Phase 2 Clinical Trial of FL115, a novel interleukin-15 (IL-15) superagonist, for nonmuscle invasive bladder cancer (NMIBC)

Source

Forlong Biotechnology

Émetteur

1.00

0

22/10/2025

Oncologie

Santé

Science

Industrie pharmaceutique

Biotechnologie

Marché du travail

Forlong Biotechology Announces Collaboration Agreement with Henlius to Develop Innovative Cancer Immunotherapy with an Engineered Cytokine

Source

Forlong Biotechnology

Émetteur

1.00

0

14/10/2025

Biotechnologie

Santé

Industrie pharmaceutique

Médecine - Divers

Oncologie

Marché du travail

Industrie

Forlong Biotechnology Receives Milestone Payment as Partner Submits IND for A Protein Therapy using its Proprietary Fbody® Technology

Source

Forlong Biotechnology

Émetteur

1.00

0

Followers

0

Compatibilité

0